IAGX (Imagenetix) EBITDA Margin %: -12.96% (As of Jun. 2015)

What is Imagenetix EBITDA Margin %?

Imagenetix IAGX -99.00% EBITDA Margin % is -12.96% as of Jun. 2015.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Imagenetix's EBITDA for the three months ended in Jun. 2015 was $-0.05 Mil. Imagenetix's Revenue for the three months ended in Jun. 2015 was $0.38 Mil. Therefore, Imagenetix's EBITDA margin for the quarter that ended in Jun. 2015 was -12.96%.

Imagenetix (OTCPK:IAGX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Imagenetix EBITDA Margin % Related Terms

Imagenetix EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Imagenetix's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imagenetix EBITDA Margin % Chart

Imagenetix Annual Data

Trend

Mar04

Mar05

Mar06

Mar07

Mar08

Mar09

Mar10

Mar11

Mar13

Mar15

EBITDA Margin %

Get a 7-Day Free Trial

12.55

-15.90

-45.63

61.66

0.00

Imagenetix Quarterly Data
	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Dec12	Mar13	Jun13	Jun14	Sep14	Dec14	Mar15	Jun15
EBITDA Margin %	Get a 7-Day Free Trial															0.00	0.00	-28.79	0.00	-12.96

IAGX vs NUVPF, ADMD, RSPI: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Imagenetix's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imagenetix EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Imagenetix's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Imagenetix's EBITDA Margin % falls into.

Save Embed

Imagenetix EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Imagenetix's EBITDA Margin % for the fiscal year that ended in Mar. 2015 is calculated as

EBITDA Margin %	=	EBITDA (A: Mar. 2015 )	/	Revenue (A: Mar. 2015 )
	=	0	/	0
	=	%

Imagenetix's EBITDA Margin % for the quarter that ended in Jun. 2015 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jun. 2015 )	/	Revenue (Q: Jun. 2015 )
	=	-0.049	/	0.378
	=	-12.96 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of -12.96% mean?

Imagenetix (IAGX) has a EBITDA Margin % of -12.96% as of Jun. 2015. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Imagenetix and its competitors.

Is Imagenetix's EBITDA Margin % too high?

Imagenetix's current EBITDA Margin % is -12.96%.

How does Imagenetix's EBITDA Margin % compare to NUVPF and ADMD?

Imagenetix's EBITDA Margin % of -12.96% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Drug Manufacturers company?

The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Imagenetix and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imagenetix's current EBITDA Margin % is -12.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Imagenetix stock overvalued right now?

Imagenetix (IAGX) has a current EBITDA Margin % of -12.96%. The current EBITDA Margin % is -12.96%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Imagenetix (IAGX), the current EBITDA Margin % is -12.96% as of Jun. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Imagenetix Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies NUVPF ADMD RSPI YBAO ULUR NRXCF ACUR LBLTF PUFXF BKIT RLMD IGC MYOS CBICF SBFM PVCT AQSZF PTLF AOLS APRI

Address 10845 Rancho Bernardo Road, Suite 105, San Diego, CA, USA, 92127

Website http://www.imagenetix.net

Imagenetix Inc is engaged in developing, formulating licensing and selling over-the-counter, natural-based nutritional supplements. Its products include Celadrin, a product formulation for joint health; and Periodyne a periodontal product. These products are offered through multiple channels of distribution, including direct marketing companies, also known as network marketing or multi-level marketing companies and chain store retailers. Geographically all the business activities are functioned primarily through the United States.